Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/12709
Full metadata record
DC FieldValueLanguage
dc.contributor.authorStojadinovic, Miroslav-
dc.contributor.authorTrifunovic M.-
dc.contributor.authorJankovic, Slobodan-
dc.date.accessioned2021-04-20T21:31:46Z-
dc.date.available2021-04-20T21:31:46Z-
dc.date.issued2020-
dc.identifier.issn0301-1623-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/12709-
dc.description.abstract© 2020, Springer Nature B.V. Purposes: The prostate biopsy collaborative group risk calculator (PBCGRC) is a newly developed risk estimator for predicting prostate biopsy outcomes. However, its clinical usefulness is still unknown within the so-called gray area of PSA values. This study aimed to determine whether updating the PBCGRC improves its predictive performance for predicting any-grade and high-grade (HG), defined as biopsy Gleason score ≥ 7, prostate cancer (PCa) in patients with prostate-specific antigen (PSA) less than 10 ng/ml. Methods: The risk of any-grade and HGPCa was calculated using the PBCG risk calculation formulas updated by recalibration in the large, logistic recalibration and model revision. Predictive performances of the PBCGRC and the updated models were compared using discrimination, calibration, and clinical utility. Results: Within the study sample of 526 patients, PCa was detected in 193 (36.7%), and 78 (14.8%) of them had HGPCa. According to the calibration curves, the PBCGRC overestimated the risk of PCa. Predictive accuracy of the revised model was higher [the area under the receiver-operating characteristic curve (AUCs), 65.4% and 70.2%] than that of the PBCGRC (AUCs, 60.4% and 64.3%) for any-grade and HGPCa. The net benefit was greater for model revision in comparison with the original model. Conclusion: The performance accuracy of PBCGRC for the prediction of any and HGPC in men undergoing prostate biopsy with PSA levels below 10 ng/ml is suboptimal. The model revision resulted with significant improvement in model performance. However, external validation of the revised model is necessary before its routine use in clinical practice.-
dc.rightsrestrictedAccess-
dc.sourceInternational Urology and Nephrology-
dc.titleAdaptation of the prostate biopsy collaborative group risk calculator in patients with PSA less than 10 ng/ml improves its performance-
dc.typearticle-
dc.identifier.doi10.1007/s11255-020-02517-8-
dc.identifier.scopus2-s2.0-85085598932-
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

144

Downloads(s)

5

Files in This Item:
File Description SizeFormat 
PaperMissing.pdf
  Restricted Access
29.86 kBAdobe PDFThumbnail
View/Open


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.